Scytovirins and Related Conjugates, Antibodies, Compositions, Nucleic Acids, Vectors, Host Cells, Methods of Production and Methods of Using Scytovirin
Description of Invention:
This invention provides: 1) isolated and purified antiviral peptides or antiviral proteins named Scytovirins isolated and purified from aqueous extracts containing the cyanobacteria, Scytonema varium; 2) an antibody which binds an epitope of Scytovirin isolated and purified from Scytonema varium; 3) a purified nucleic acid molecule that comprises a sequence which encodes an amino acid sequence homologous to Scytovirin; 4) a vector comprising the isolated and purified nucleic acid molecule and a host cell or organism comprising the vector; 5) a conjugate comprising the peptide and an effector component; and 6) a method of inhibiting prophylactically and therapeutically a viral infection. Thus, this invention may represent potential new therapeutics for treatment of retroviral infections, including AIDS.
Inventors:
Michael R. Boyd (NCI) Barry R. O'Keefe (NCI) Tawnya C. McKee (NCI) Heidi R. Bokesch (SAIC)
Patent Status:
DHHS Reference No. E-017-2002/0 --
U.S. Provisional Application No. 60/381,322 filed 16 May 2002
PCT Application No. PCT/US03/15991 filed 15 May 2003, which published as WO 03/097814 on 27 Nov 2003
U.S. Patent Application No. 10/513,961 filed 10 Nov 2004
Relevant Publication:
H.R. Bokesch et al., "A Potent Anti-HIV Protein from the Cultured Cyanobacteria Scytonema varium," Biochemistry, 2003, 42, 2578-2584
For Additional Information Please Contact: Sally Hu PhD MBA
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301) 435-5606
Email: hus@mail.nih.gov
Fax: (301) 402-0220
